Pulmonary Surfactant Discovery Transformed Care for Newborns with Respiratory Distress
Start here
Neonatal respiratory distress syndrome (RDS) once killed more than 90% of premature infants who developed it. Research established that the core cause was a deficiency of pulmonary surfactant, a protein-lipid complex that lines the lungs. That finding led to replacement therapy, which progressed through physiological measurements, animal studies and clinical trials to FDA approval. The treatment cut mortality in neonatal intensive care to under 5%, and surfactant replacement became routine care roughly 40 years after the field began. An iBiology Science Stories lecture traces this arc from discovery to standard of care. The story is a historical account; no open clinical or regulatory questions are in play.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comiBiology Lecture Traces Surfactant Discovery and the Fight Against Neonatal Respiratory Distress
An iBiology Science Stories lecture traces the discovery of pulmonary surfactant and its role in neonatal respiratory distress syndrome (RDS). Decades ago, mortality among premature infants with RDS exceeded 90%; research showed that a deficiency of surfactant, a protein-lipid complex, was the core cause. Replacement therapy, developed through physiological measurements, animal and clinical trials to FDA approval, cut neonatal intensive care mortality to under 5%, with surfactant becoming routine care roughly 40 years after the field began.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.